LISTED pharmaceutical company Mayne Pharma may take Federal Court action to revive its failed push to have its longer-life (12-hour) generic oxycodone pain relief product introduced into Australia.
Already supplying four to six hour oxycodone products in Australia, the company was unable to convince the Administrative Appeals Tribunal to register its 12-hour version.
According to a Fairfax report, the company may take the case to the Federal Court with new evidence supporting the product.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Oct 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Oct 17
